The approval followed previously conducted trials enrolling patients with transfusional iron overload and evidence of inadequate iron removal despite previous treatment with deferoxamine.
The standard of care to treat transfusional iron overload is chelation therapy, where chemical agents that are used to remove heavy metals from the body.
Ferriprox is intended for use when chelation therapy is inadequate.